Tourette Syndrome - Double-Blind Placebo Control Safety and Feasibility Study

Shalvata Mental Health Center, Hod-Hasharon, Israel

3 October, 2010

A clinical trial of Brainsway's Deep TMS device for the treatment of subjects with Tourette syndrome has begun at the Shalvata Mental Health Center.

Tourrette syndrome is a developmental neuropsychiatric disorder whose onset typically occurs in childhood. The disorder is characterized by transient and stereotyped movements and vocalizations called tics. Common tics include jerking movements of the neck, shoulders or limbs, sniffing, throat clearing, grunting, etc. 

The present trial is an open study. Approximately 20 patients diagnosed with Tourette syndrome and receiving drug treatment or some form of psychotherapy, or both, will participate in the trial. Subjects recruited into the trial will receive trains of transcranial magnetic stimulation 5 days a week for 4 weeks. Evaluations of the severity of Tourette syndrome-associated symptoms will be performed at 4 time-points over the course of the trial: During the initial screening process, at the end of the first two weeks of treatment, at the conclusion of the entire treatment period (after 4 weeks) and again one week after the end of treatment.